仙琚制药：签订1.1类新药阿更葡糖钠注射液相关协议 与杭州奥默商业化里程碑分成比例为各50%

Core Viewpoint - Xianju Pharmaceutical has entered into a tripartite agreement with Hangzhou Aomei and Aishijian for the exclusive marketing of Ageng Glucosamine Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The agreement designates Aishijian as the exclusive marketing service provider for Ageng Glucosamine Sodium Injection in mainland China [1] - Xianju Pharmaceutical and Hangzhou Aomei have established a milestone revenue-sharing agreement, with both parties sharing 50% of the commercialization milestone revenue [1] - The net revenue from commercialization sales in mainland China will also be shared equally, with both companies receiving 50% after deducting relevant expenses [1] Group 2 - Xianju Pharmaceutical and Hangzhou Aomei have signed a procurement supply agreement for the raw materials of Ageng Glucosamine Sodium and a supplementary agreement for the commissioned production of the injection [1] - Ageng Glucosamine Sodium Injection is classified as a Class 1 new drug and is a targeted muscle relaxant [1]